A new investigational treatment has shown strong and lasting responses in multiple myeloma patients with extramedullary ...

UCB has announced new three-year data from phase 3 trials and their open-label extensions investigating BIMZELX (bimekizumab) ...

Santen has announced that the European Commission has granted market authorisation for Ryjunea, a low-dose atropine eye drop ...

Argenx has presented positive phase 2 results for efgartigimod in myositis and Sjogren’s disease at EULAR 2025. The company ...

Levicept has presented new data from its phase 2 trial of LEVI-04 at the European Congress of Rheumatology (EULAR 2025). The ...

In a move to progress treatment efficacy, oncologists widely agree that, in the future, cancer treatments will become ...

Birmingham spin-out Linear Diagnostics has secured £1m funding to advance a rapid test for sexually transmitted infections ...

The PharmaTimes Clinical Researcher of the Year – The Americas 2025 Awards offer an unparalleled opportunity to showcase your ...

The European Migraine and Headache Alliance (EMHA) has urged EU policymakers to include migraine in the forthcoming ...

Tagomics has been awarded £860k in funding from Innovate UK’s Biomedical Catalyst programme to develop a novel diagnostic ...

Tozaro has announced the appointment of Dr Jason Slingsb y as Chief Executive Officer. Jason will lead the company’s ...